This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Grabinski, J. L. Search for Related Content Social Bookmarking                   What's this?

Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice

Center for Pharmacogenomic Research, University of Texas College of Pharmacy, grabinski{at}uthscsa.edu

Hematology and oncology have been two of the leading areas in pharmacogenomics. The use of genetic information to guide therapy has been practiced for a number of years. The identification of polymorphisms within drug-metabolizing enzymes of anticancer agents such as 6-mercaptopurine and irinotecan has led to subsequent changes in package-insert labeling and tests approved by the US Food and Drug Administration to identify polymorphisms. Many studies within oncology are now conducting pharmacogenomic analyses in drug development to identify predictors of response and/or toxicity. For clinical pharmacists, knowledge in the area of pharmacogenomics and drug metabolism is important to understand and integrate pharmacogenomics into clinical practice. This article will review a number of different agents used in the realm of oncology and will identify how pharmacogenomics has or will potentially affect treatment decisions in the future with the goal of improving patient care and outcomes.

Key Words: Pharmacogenomics • oncology • drug metabolism • polymorphism.

Journal of Pharmacy Practice, Vol. 20, No. 3, 246-251 (2007)
DOI: 10.1177/0897190007304822


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?